Drug Profile

Atropine dry-powder inhalation - MicroDose Therapeutx

Alternative Names: Atropine sulfate dry-powder inhalation - MicroDose Therapeutx; MDT-010

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MicroDose Therapeutx
Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
Mechanism of Action Cholinergic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Poisoning

Most Recent Events

24 Mar 2016 No recent reports on development identified - Phase-I for Poisoning (In volunteers) in USA (Inhalation)
08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
24 Sep 2009 Phase-I clinical trials in Poisoning in USA (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com